Sign In
Buy ALT
$2.87
-0.0300 (-1.03%)
At Close: Jun 03, 2026
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
12:47pm, Monday, 04'th Dec 2023
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
Why Is Altimmune (ALT) Stock Up 43% Today?
11:45am, Friday, 01'st Dec 2023
Altimmune (NASDAQ: ALT ) stock is rising higher on Friday after the company posted positive results from a weight loss drug trial. Those results come from the biopharmaceutical company's Phase 2 obesi
Here's why penny stocks like GGE, NEXI, ALT, HCDI are pumping
10:59am, Friday, 01'st Dec 2023
Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by mo
5 Hot Penny Stocks To Watch In The Stock Market Today
09:19am, Wednesday, 25'th Oct 2023
Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, understanding things like stock market news and events
GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic
Altimmune to Participate at Two Upcoming Investor Conferences
07:30am, Tuesday, 17'th Oct 2023
GAITHERSBURG, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti
Altimmune: A Year Of Disappointment
03:46am, Wednesday, 11'th Oct 2023
Altimmune's stock has disappointed shareholders over the past year, with disappointing trial results triggering a significant drop in equity in March of this year. The Company is developing treatments
Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch ASAP
03:27pm, Friday, 15'th Sep 2023
Penny stocks, typically defined as stocks trading under $5 per share, offer traders massive upside profit potential but also higher risk due to greater volatility. When penny stocks become heavily sho
Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study
09:01am, Wednesday, 13'th Sep 2023
Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023.
Altimmune to Participate at Two Upcoming Investor Conferences
07:30am, Wednesday, 30'th Aug 2023
GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti
Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
07:30am, Thursday, 03'rd Aug 2023
GAITHERSBURG, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2023 financial re
As Ozempic/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion
05:05am, Friday, 21'st Jul 2023
Morgan Stanley on Friday lifted its forecast for annual sales of weight-loss drugs to $77 billion, as patient demand for the medicines has outstripped supply and been fueled by a social-media frenzy.
Factbox: Weight-loss drugs: the next gold rush
10:56am, Tuesday, 27'th Jun 2023
Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.
GAITHERSBURG, Md., June 16, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmun
Altimmune to Participate at Two Upcoming Investor Conferences
07:30am, Wednesday, 31'st May 2023
GAITHERSBURG, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will partic
